Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.

…read more

Source: Bristol, Sanofi and Novartis lead pack in big year for blockbusters


0 No comments